Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Improving diagnosis of genitourinary cancers: Biomarker discovery strategies through mass spectrometry-based metabolomics.

Manzi M, Riquelme G, Zabalegui N, Monge ME.

J Pharm Biomed Anal. 2020 Jan 30;178:112905. doi: 10.1016/j.jpba.2019.112905. Epub 2019 Oct 7. Review.

PMID:
31707200
2.

Metabolic Footprinting of a Clear Cell Renal Cell Carcinoma in Vitro Model for Human Kidney Cancer Detection.

Knott ME, Manzi M, Zabalegui N, Salazar MO, Puricelli LI, Monge ME.

J Proteome Res. 2018 Nov 2;17(11):3877-3888. doi: 10.1021/acs.jproteome.8b00538. Epub 2018 Oct 12.

PMID:
30260228
3.

Prolonged idiotypic vaccination against follicular lymphoma.

Inoges S, Lopez-Diaz de Cerio A, Zabalegui N, Soria E, Villanueva H, Panizo C, Rodriguez-Caballero A, Suarez L, Pastor F, Rodriguez-Calvillo M, Orfao A, Bendandi M.

Leuk Lymphoma. 2009 Jan;50(1):47-53. doi: 10.1080/10428190802601122.

4.

TAK1 mRNA expression in the tumor tissue of locally advanced head and neck cancer patients.

Honorato B, Alcalde J, Martinez-Monge R, Zabalegui N, Garcia-Foncillas J.

Gene Regul Syst Bio. 2008 Feb 14;2:63-70.

5.

[Idiotype vaccines in the treatment of follicular lymphoma: current status and future perspectives].

Zabalegui N, López Díaz de Cerio A, Inogés S, Soria E, Villanueva H, Rivero P.

An Sist Sanit Navar. 2009 Jan-Apr;32(1):61-73. Review. Spanish.

6.

Anti-idiotype antibodies in cancer treatment.

de Cerio AL, Zabalegui N, Rodríguez-Calvillo M, Inogés S, Bendandi M.

Oncogene. 2007 May 28;26(25):3594-602. Review.

7.

Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer.

Salgado J, Zabalegui N, Gil C, Monreal I, Rodríguez J, García-Foncillas J.

Oncol Rep. 2007 Feb;17(2):325-8.

PMID:
17203168
8.

Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor.

Radcliffe CM, Arnold JN, Suter DM, Wormald MR, Harvey DJ, Royle L, Mimura Y, Kimura Y, Sim RB, Inogès S, Rodriguez-Calvillo M, Zabalegui N, de Cerio AL, Potter KN, Mockridge CI, Dwek RA, Bendandi M, Rudd PM, Stevenson FK.

J Biol Chem. 2007 Mar 9;282(10):7405-15. Epub 2006 Dec 29.

9.

Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma.

Inogès S, Rodrìguez-Calvillo M, Zabalegui N, Lòpez-Dìaz de Cerio A, Villanueva H, Soria E, Suárez L, Rodríguez-Caballero A, Pastor F, García-Muñóz R, Panizo C, Pèrez-Calvo J, Melero I, Rocha E, Orfao A, Bendandi M; Grupo Español de Linfomas/Trasplante Autologo de Medula Oseo study group; Programa para el Estudio y Tratamiento de Hemopatias Malignas study group.

J Natl Cancer Inst. 2006 Sep 20;98(18):1292-301.

PMID:
16985248
10.

Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation.

Bendandi M, Rodríguez-Calvillo M, Inogés S, López-Díaz de Cerio A, Pérez-Simón JA, Rodríguez-Caballero A, García-Montero A, Almeida J, Zabalegui N, Giraldo P, San Miguel J, Orfao A.

Leuk Lymphoma. 2006 Jan;47(1):29-37.

PMID:
16321824
11.

Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression.

Bandres E, Andion E, Escalada A, Honorato B, Catalan V, Cubedo E, Cordeu L, Garcia F, Zarate R, Zabalegui N, Garcia-Foncillas J.

J Neurooncol. 2005 Jul;73(3):189-98.

PMID:
15980968
12.

Structure-based assessment of BRCA1 and BRCA2 mutations in a small Spanish population.

Salgado J, Zabalegui N, García-Amigot F, Gil MC, González MS, García-Foncillas J.

Oncol Rep. 2005 Jul;14(1):85-8.

PMID:
15944772
13.

[Past, present and future of anti-idiotype vaccination].

Rodríguez Calvillo M, Inogés S, López Díaz de Cerio A, Zabalegui N, Panizo C, Hernández M, Pérez Calvo J, Prósper F, Melero I, Sánchez-Ibarrola A, Rocha E, Bendandi M.

Rev Med Univ Navarra. 2004 Jul-Sep;48(3):14-23. Review. Spanish.

PMID:
15622921
14.

Variations in "rescuability" of immunoglobulin molecules from different forms of human lymphoma: implications for anti-idiotype vaccine development.

Rodríguez-Calvillo M, Inogés S, López-Díaz de Cerio A, Zabalegui N, Villanueva H, Bendandi M.

Crit Rev Oncol Hematol. 2004 Oct;52(1):1-7. Review.

PMID:
15363462
15.

Dysregulation of apoptosis is a major mechanism in the lymph node involvement in colorectal carcinoma.

Bandres E, Catalan V, Sola I, Honorato B, Cubedo E, Cordeu L, Andion E, Escalada A, Zarate R, Salgado E, Zabalegui N, García F, Garcia-Foncillas J.

Oncol Rep. 2004 Aug;12(2):287-92.

PMID:
15254690
16.

Alpha CP-4, encoded by a putative tumor suppressor gene at 3p21, but not its alternative splice variant alpha CP-4a, is underexpressed in lung cancer.

Pio R, Zudaire I, Pino I, Castaño Z, Zabalegui N, Vicent S, Garcia-Amigot F, Odero MD, Lozano MD, Garcia-Foncillas J, Calasanz MJ, Montuenga LM.

Cancer Res. 2004 Jun 15;64(12):4171-9.

17.

[Active immunotherapy in the treatment of haematological neoplasias].

Inogés S, Rodríguez Calvillo M, López Díaz de Cerio A, Zabalegui N, Melero I, Sánchez Ibarrola A, Rocha E, Bendandi M.

An Sist Sanit Navar. 2004 Jan-Apr;27(1):45-62. Review. Spanish.

18.

Acquired potential N-glycosylation sites within the tumor-specific immunoglobulin heavy chains of B-cell malignancies.

Zabalegui N, de Cerio AL, Inogés S, Rodríguez-Calvillo M, Pérez-Calvo J, Hernández M, García-Foncillas J, Martín-Algarra S, Rocha E, Bendandi M.

Haematologica. 2004 May;89(5):541-6.

19.

Feasibility of idiotype vaccination in relapsed B-cell malignancies.

Inogés S, Rodríguez-Calvillo M, López-Díaz de Cerio A, Zabalegui N, Pérez-Calvo J, Panizo C, Hernandez M, Cuesta B, Rocha E, Bendandi M.

Haematologica. 2003 Dec;88(12):1438-40. No abstract available.

20.

Non-radiolabelled PCR consensus primers and automatic sequencing enable rapid identification of tumor-specific V(H) CDR3 in aggressive B-cell malignancies.

Pession A, Tonelli R, Canderan G, Bendandi M, Rosolen A, Basso K, Basso G, Locatelli F, Zabalegui N, Paolucci G.

Leuk Lymphoma. 2003 Sep;44(9):1597-601.

PMID:
14565664
21.

Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer.

Pino I, Pío R, Toledo G, Zabalegui N, Vicent S, Rey N, Lozano MD, Torre W, García-Foncillas J, Montuenga LM.

Lung Cancer. 2003 Aug;41(2):131-43.

22.

A multidrug resistance 3 gene mutation causing cholelithiasis, cholestasis of pregnancy, and adulthood biliary cirrhosis.

Lucena JF, Herrero JI, Quiroga J, Sangro B, Garcia-Foncillas J, Zabalegui N, Sola J, Herraiz M, Medina JF, Prieto J.

Gastroenterology. 2003 Apr;124(4):1037-42.

PMID:
12671900
23.

Weight loss in tumour-bearing mice is not associated with changes in resistin gene expression in white adipose tissue.

Gómez-Ambrosi J, Zabalegui N, Bing C, Tisdale MJ, Trayhurn P, Williams G.

Horm Metab Res. 2002 Nov-Dec;34(11-12):674-7.

PMID:
12660881
24.

Resistin and RELM-alpha gene expression in white adipose tissue of lactating mice.

Bing C, Gomez-Ambrosi J, Zabalegui N, Williams G, Trayhurn P.

Biochem Biophys Res Commun. 2002 Aug 16;296(2):458-62.

PMID:
12163041
25.

Evidence that heparin but not hirudin reduces PAI-1 expression in cultured human endothelial cells.

Orbe J, Montes R, Zabalegui N, Pérez-Ruiz A, Páramo JA.

Thromb Res. 1999 May 1;94(3):137-45.

26.

Prevalence of FVR506Q and prothrombin 20210A mutations in the Navarrese population.

Zabalegui N, Montes R, Orbe J, Ayape ML, Medarde A, Páramo JA, Rocha E.

Thromb Haemost. 1998 Sep;80(3):522-3. No abstract available.

PMID:
9759640
27.

[Other acquired hypercoagulable states].

Rocha E, Montes R, Hermida J, Orbe I, Zabalegui N.

Sangre (Barc). 1997 Dec;42(6):483-92. Review. Spanish. No abstract available.

PMID:
9490913

Supplemental Content

Loading ...
Support Center